Indaptus Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for INDP, updated each market day.
INDP AI Sentiment
AI predicts Indaptus Therapeutics, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Sector
Exchange
Market Cap
$4,148,299
Cap Tier
Employees
5
Headquarters
NEW YORK, NY
Listed Since
Aug. 4, 2021
Website
INDP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INDP Volatility
Indaptus Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
